Tags

Type your tag names separated by a space and hit enter

Synthesis, pharmacological assessment, molecular modeling and in silico studies of fused tricyclic coumarin derivatives as a new family of multifunctional anti-Alzheimer agents.
Eur J Med Chem. 2016 Jan 01; 107:219-32.EJ

Abstract

A series of fused tricyclic coumarin derivatives bearing iminopyran ring connected to various amido moieties were developed as potential multifunctional anti-Alzheimer agents for their cholinesterase inhibitory and radical scavenging activities. In vitro studies revealed that most of these compounds exhibited high inhibitory activity on acetylcholinesterase (AChE), with IC50 values ranging from 0.003 to 0.357 μM which is 2-220 folds more potent than the positive control, galantamine. Their inhibition selectivity against AChE over butyrylcholinesterase (BuChE) has increased about 194 fold compared with galantamine. The developed compounds also showed potent ABTS radical scavenging activity (IC50 7.98-15.99 μM). Specifically, the most potent AChE inhibitor 6n (IC50 0.003 ± 0.0007 μM) has an excellent antioxidant profile as determined by the ABTS method (IC50 7.98 ± 0.77 μM). Moreover, cell viability studies in SK N SH cells showed that the compounds 6m-q have significant neuroprotective effects against H2O2-induced cell death, and are not neurotoxic at all concentrations except 6n and 6q. The kinetic analysis of compound 6n proved that it is a mixed-type inhibitor for EeAChE (Ki1 0.0103 μM and Ki2 0.0193 μM). Accordingly, the molecular modeling study demonstrated that 6m-q with substituted benzyl amido moiety possessed an optimal docking pose with interactions at catalytic active site (CAS) and peripheral anionic site (PAS) of AChE simultaneously and thereby they might prevent aggregation of Aβ induced by AChE. Furthermore, in silico ADMET prediction studies indicated that these compounds satisfied all the characteristics of CNS acting drugs. Most active inhibitor 6n is permeable to BBB as determined in the in vivo brain AChE activity. To sum up, the multipotent therapuetic profile of these novel tricyclic coumarins makes them promising leads for developing anti-Alzheimer agents.

Authors+Show Affiliations

Department of Chemistry, Yogi Vemana University, Kadapa, India.Centre for Bioinformatics, School of Life Sciences, Pondicherry Central University, Puducherry, India.Department of Chemistry, Yogi Vemana University, Kadapa, India.Centre for Bioinformatics, School of Life Sciences, Pondicherry Central University, Puducherry, India.Department of Chemistry, University College of Sciences, Sri Venkateswara University, Tirupati, India.Department of Biotechnology and Bioinformatics, Yogi Vemana University, Kadapa, India.Department of Chemistry, University College of Sciences, Sri Venkateswara University, Tirupati, India.Centre for Bioinformatics, School of Life Sciences, Pondicherry Central University, Puducherry, India.Department of Biotechnology and Bioinformatics, Yogi Vemana University, Kadapa, India.Department of Chemistry, Yogi Vemana University, Kadapa, India. Electronic address: agdamu01@gmail.com.

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

26588065

Citation

Shaik, Jeelan Basha, et al. "Synthesis, Pharmacological Assessment, Molecular Modeling and in Silico Studies of Fused Tricyclic Coumarin Derivatives as a New Family of Multifunctional anti-Alzheimer Agents." European Journal of Medicinal Chemistry, vol. 107, 2016, pp. 219-32.
Shaik JB, Palaka BK, Penumala M, et al. Synthesis, pharmacological assessment, molecular modeling and in silico studies of fused tricyclic coumarin derivatives as a new family of multifunctional anti-Alzheimer agents. Eur J Med Chem. 2016;107:219-32.
Shaik, J. B., Palaka, B. K., Penumala, M., Kotapati, K. V., Devineni, S. R., Eadlapalli, S., Darla, M. M., Ampasala, D. R., Vadde, R., & Amooru, G. D. (2016). Synthesis, pharmacological assessment, molecular modeling and in silico studies of fused tricyclic coumarin derivatives as a new family of multifunctional anti-Alzheimer agents. European Journal of Medicinal Chemistry, 107, 219-32. https://doi.org/10.1016/j.ejmech.2015.10.046
Shaik JB, et al. Synthesis, Pharmacological Assessment, Molecular Modeling and in Silico Studies of Fused Tricyclic Coumarin Derivatives as a New Family of Multifunctional anti-Alzheimer Agents. Eur J Med Chem. 2016 Jan 1;107:219-32. PubMed PMID: 26588065.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Synthesis, pharmacological assessment, molecular modeling and in silico studies of fused tricyclic coumarin derivatives as a new family of multifunctional anti-Alzheimer agents. AU - Shaik,Jeelan Basha, AU - Palaka,Bhagath Kumar, AU - Penumala,Mohan, AU - Kotapati,Kasi Viswanath, AU - Devineni,Subba Rao, AU - Eadlapalli,Siddhartha, AU - Darla,M Manidhar, AU - Ampasala,Dinakara Rao, AU - Vadde,Ramakrishna, AU - Amooru,G Damu, Y1 - 2015/10/31/ PY - 2015/07/15/received PY - 2015/10/23/revised PY - 2015/10/28/accepted PY - 2015/11/21/entrez PY - 2015/11/21/pubmed PY - 2016/9/22/medline KW - ADMET KW - Acetylcholinesterase KW - Alzheimer's disease KW - Antioxidant KW - Butyrylcholinesterase KW - Fused tricyclic coumarin KW - Molecular modeling study KW - Neuroprotection SP - 219 EP - 32 JF - European journal of medicinal chemistry JO - Eur J Med Chem VL - 107 N2 - A series of fused tricyclic coumarin derivatives bearing iminopyran ring connected to various amido moieties were developed as potential multifunctional anti-Alzheimer agents for their cholinesterase inhibitory and radical scavenging activities. In vitro studies revealed that most of these compounds exhibited high inhibitory activity on acetylcholinesterase (AChE), with IC50 values ranging from 0.003 to 0.357 μM which is 2-220 folds more potent than the positive control, galantamine. Their inhibition selectivity against AChE over butyrylcholinesterase (BuChE) has increased about 194 fold compared with galantamine. The developed compounds also showed potent ABTS radical scavenging activity (IC50 7.98-15.99 μM). Specifically, the most potent AChE inhibitor 6n (IC50 0.003 ± 0.0007 μM) has an excellent antioxidant profile as determined by the ABTS method (IC50 7.98 ± 0.77 μM). Moreover, cell viability studies in SK N SH cells showed that the compounds 6m-q have significant neuroprotective effects against H2O2-induced cell death, and are not neurotoxic at all concentrations except 6n and 6q. The kinetic analysis of compound 6n proved that it is a mixed-type inhibitor for EeAChE (Ki1 0.0103 μM and Ki2 0.0193 μM). Accordingly, the molecular modeling study demonstrated that 6m-q with substituted benzyl amido moiety possessed an optimal docking pose with interactions at catalytic active site (CAS) and peripheral anionic site (PAS) of AChE simultaneously and thereby they might prevent aggregation of Aβ induced by AChE. Furthermore, in silico ADMET prediction studies indicated that these compounds satisfied all the characteristics of CNS acting drugs. Most active inhibitor 6n is permeable to BBB as determined in the in vivo brain AChE activity. To sum up, the multipotent therapuetic profile of these novel tricyclic coumarins makes them promising leads for developing anti-Alzheimer agents. SN - 1768-3254 UR - https://www.unboundmedicine.com/medline/citation/26588065/Synthesis_pharmacological_assessment_molecular_modeling_and_in_silico_studies_of_fused_tricyclic_coumarin_derivatives_as_a_new_family_of_multifunctional_anti_Alzheimer_agents_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S0223-5234(15)30328-7 DB - PRIME DP - Unbound Medicine ER -